MARKET

ALZN

ALZN

Alzamend Neuro, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.73
-0.01
-0.17%
After Hours: 5.66 -0.07 -1.22% 19:59 07/23 EDT
OPEN
8.14
PREV CLOSE
5.74
HIGH
8.28
LOW
5.63
VOLUME
28.19M
TURNOVER
--
52 WEEK HIGH
33.55
52 WEEK LOW
4.850
MARKET CAP
486.65M
P/E (TTM)
-96.4646
1D
5D
1M
3M
1Y
5Y
DPW, ANVS and CFMS among pre market gainers
Socket Mobile (SCKT) +79% on Q2 earningsAlzamend Neuro (ALZN) +62% after data showing safety of Alzheimer’s therapy in mouse studyVeoneer (VNE) +55% on earningsAcorda Therapeutics (ACOR) +49% on INBRIJA distribution and supply dealNRx Pharmaceuticals (NRXP...
Seekingalpha · 1d ago
Alzamend Neuro surges after data showing safety of Alzheimer’s therapy in mouse study
selvanegra/iStock via Getty Images Alzamend Neuro (ALZN) has climbed ~77.5% in the pre-market after the company announced positive results for its experimental Alzheimer’s candidate AL002 in a mouse model with the disease.
Seekingalpha · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Investor Place · 1d ago
Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models
Benzinga · 1d ago
Alzamend Neuro Sees Positive Toxicology Results for Alzheimer's Therapy in Study
marketwatch.com · 1d ago
BRIEF-Alzamend Neuro Receives Positive Results For AL002 In Study
reuters.com · 1d ago
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
TAMPA, Fla., July 23, 2021--Alzamend Neuro Receives Positive Results for AL002, a Mutant-Peptide Vaccine, in GLP CRL Tox Study Using Alzheimer's Disease Transgenic Mouse Model
Business Wire · 1d ago
Sector Update: Health Care
MT Newswires · 1d ago
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALZN. Analyze the recent business situations of Alzamend Neuro, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About ALZN
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

Webull offers kinds of Alzamend Neuro Inc stock information, including NASDAQ:ALZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALZN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALZN stock methods without spending real money on the virtual paper trading platform.